Non-peptide arginine-vasopressin antagonists: the vaptans.
about
Treatment of euvolemic hyponatremia in the intensive care unit by ureaUsefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patientsTreatment and management of ascites and hepatorenal syndrome: an updateNovel treatment targets for cerebral edemaPhysiopathology, clinical diagnosis, and treatment of hyponatremia.New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in childrenTolvaptan.Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literatureMortality after hospitalization with mild, moderate, and severe hyponatremia.Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis.Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia.Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressinA review of drug-induced hypernatraemia.The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Basal Plasma Levels of Copeptin are Elevated in Inactive Inflammatory Bowel Disease after Bowel Resection.Vasopressin receptor antagonists and their role in clinical medicine.A green synthetic approach toward the synthesis of structurally diverse spirooxindole derivative libraries under catalyst-free conditions.Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.Arginine Vasopressin Injected into the Dorsal Motor Nucleus of the Vagus Inhibits Gastric Motility in RatsAsymmetric catalytic aza-Morita-Baylis-Hillman reaction for the synthesis of 3-substituted-3-aminooxindoles with chiral quaternary carbon centersSevere Hyponatremia with Hypouricemia in a Patient with Medullary Hemorrhage: A Case ReportNovel diuretic targetsACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase.SIADH and hyponatraemia: why does it matter?Vasopressin-receptor antagonists.Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?Management of hypotonic hyponatremia.The therapeutic use of vaptans for the treatment of dilutional hyponatremia.The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice.Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.Vasopressin: a novel target for the prevention and retardation of kidney disease?Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists.Vasopressin receptor antagonists: from pivotal trials to current practice.Role of vasopressin and its antagonism in stroke related edema.Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis.Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study.
P2860
Q21194912-C0CC57C0-88A8-47F9-9AFF-A71EECE00B26Q24658600-42C79BB4-EE57-47BC-8CE4-D1BF2D50D1E6Q27000268-31B87703-904F-432B-8A74-E8858C208C6EQ28254203-2DCD8F2C-96CA-42AD-83FA-0B3D98D2646DQ30240732-9362EBBA-B1D6-4434-8D81-655C4B1964A5Q33866957-81A6C9B3-0F1C-44EA-9CB5-234AEAE8F244Q34052281-1599B132-13F1-43DC-9FE3-8B714EC74356Q34544328-81783A29-14C5-4F29-A424-A3C82993A1C3Q34551988-1D7193A9-B387-4AD6-B18B-A9CD594A2897Q34636917-BE4B1220-F6DB-4C29-9F75-1C57F2EE022AQ34674591-135C8A16-55A7-4FC9-A8C7-D4FFA3A91390Q34726918-0511D2A1-4C80-4252-98A7-1F722B52A691Q35275760-49429571-E9C0-4266-87D3-65E4917F30F3Q35543229-A025C05D-460D-429B-A21A-86BB7A6BDA62Q35574010-21E9484B-25E9-4A8B-B1A0-28332E129A57Q35606442-D38BC90D-9B55-46C4-9A64-187E5E0F9B7AQ35657152-552CEED7-2D31-41A2-A2B9-481EFC62BABAQ35850091-C5245177-8BE4-4271-9797-176710C26537Q35856033-C57DD001-AB81-49DD-88F4-1D3F6648F259Q36278024-981DFE7D-A376-4EAA-B9C5-4A63137C1438Q36329310-CD34E9F0-55B2-4968-819F-B676317A3D9BQ36457264-4AFAC850-5480-4D39-B5ED-606CB4E8CE41Q36662095-C90356BF-74C5-4E16-9193-E208FCDA4076Q37155115-69DCCEB7-7F57-49A8-BE6E-900CFDD35917Q37234799-86A5FD52-0CAE-493E-A542-23FBC6AE89E1Q37356843-5B466707-5AE1-4AA2-9B1B-F4E925EED569Q37389306-8307E2E3-861C-4592-B290-203786B0E99EQ37770574-B31BA5D6-B668-498B-B5CB-2F12CD9D3323Q37786447-A0744457-9C23-4244-B9B3-927F6B855FEDQ37832491-3DC41620-7827-4DB7-9ABF-769E2DB90AA3Q37911141-9B640770-0770-4FA2-93EF-4591641DA89BQ37950893-9BD3A8AB-11DD-4793-A913-5137D9D51864Q37959051-B207F316-3B1F-4786-80AD-012E33D87C2CQ38084471-5073129B-EADF-4CC8-9CCE-7AFBA5359A3FQ38086800-202E7301-4872-4106-9C1E-4B1E7CC3981EQ38107508-0D2E2DB8-A840-4688-B9F2-05303D71CCF4Q38160378-18ED0E5F-A747-4AC2-9A6B-BE8E76B11E81Q38211471-F12EFDF7-0305-410D-B97C-EE061EA8F921Q38271966-55D1D0D9-8F46-444A-A9A2-DA9E2ABFE9F5Q38496208-3F7E2C07-899D-4774-B0A7-B1E0F5DF3858
P2860
Non-peptide arginine-vasopressin antagonists: the vaptans.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Non-peptide arginine-vasopressin antagonists: the vaptans.
@ast
Non-peptide arginine-vasopressin antagonists: the vaptans.
@en
Non-peptide arginine-vasopressin antagonists: the vaptans.
@nl
type
label
Non-peptide arginine-vasopressin antagonists: the vaptans.
@ast
Non-peptide arginine-vasopressin antagonists: the vaptans.
@en
Non-peptide arginine-vasopressin antagonists: the vaptans.
@nl
prefLabel
Non-peptide arginine-vasopressin antagonists: the vaptans.
@ast
Non-peptide arginine-vasopressin antagonists: the vaptans.
@en
Non-peptide arginine-vasopressin antagonists: the vaptans.
@nl
P2093
P1433
P1476
Non-peptide arginine-vasopressin antagonists: the vaptans.
@en
P2093
Alain Soupart
Gilbert Vassart
Guy Decaux
P304
P356
10.1016/S0140-6736(08)60695-9
P407
P577
2008-05-01T00:00:00Z